MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

uniQure NV

Închisă

10.6 7.07

Rezumat

Modificarea prețului

24h

Curent

Minim

9.68

Maxim

10.78

Indicatori cheie

By Trading Economics

Venit

-29M

-73M

Vânzări

2.9M

5.2M

EPS

-1.442

Marjă de profit

-1,403.199

Angajați

209

EBITDA

-28M

-53M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+266.2% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

84M

674M

Deschiderea anterioară

3.53

Închiderea anterioară

10.6

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

uniQure NV Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 dec. 2024, 15:18 UTC

Principalele dinamici ale pieței

UniQure Shares Double After FDA Agreement on Pathway for Huntington's Disease Treatment

Comparație

Modificare preț

uniQure NV Așteptări

Obiectiv de preț

By TipRanks

266.2% sus

Prognoză pe 12 luni

Medie 36.29 USD  266.2%

Maxim 70 USD

Minim 18 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruuniQure NV - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

8

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

9.38 / 14.95Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.